Sloning BioTechnology Starting Feasibility Study to Improve the Efficiency of an Enzyme Used in Molecular Diagnostic Applications for bioMérieux.
News Aug 14, 2007
Sloning BioTechnology GmbH, technology leader in the emerging gene synthesis market and provider of gene mutant libraries (SlonoMax™), will carry out a feasibility study together with bioMérieux.
The aim of the project is to generate a large number of different gene variants of an essential enzyme to be used in diagnostic applications.
Sloning will use its Slonomics™ industrial scale gene synthesis technology to provide a gene library with a full set of ratio-controlled mutants. The successful completion of the study will enable bioMérieux to identify an enzyme with significantly enhanced characteristics.
“We are very excited about this collaboration. It gives Sloning the opportunity to demonstrate the capabilities of our enabling technology in the field of protein engineering and synthetic biology and in this particular case with a significant commercial impact to our customer.” stated Dr. Heinz Schwer, the company CEO.